Status:
COMPLETED
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Boston Children's Hospital
Conditions:
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
5-39 years
Phase:
PHASE2
PHASE3
Brief Summary
This is a pilot clinical trial to assess whether the administration of diltiazem may be able to decrease the development or progression of hypertrophic cardiomyopathy (HCM). Diltiazem is a commonly us...
Detailed Description
STUDY RATIONALE: Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by histopathologic findings of cardiac myocyte disarray and fibrosis, and clinical manifestations of unexplained...
Eligibility Criteria
Inclusion
- Preclinical HCM (identified sarcomere mutation with no clinical evidence of left ventricular hypertrophy)
- Able to provide informed consent (or parental consent)
Exclusion
- Contraindication to diltiazem administration
- Impaired hepatic or renal function
- Age \< 5 years
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00319982
Start Date
January 1 2006
End Date
December 1 2013
Last Update
April 7 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
2
Children's Hospital
Boston, Massachusetts, United States, 02115